Physician profile
Yasser Jamil
NPI 1568034197
$1,073.42
in general payments reported to CMS, 2019-2025
11 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $371 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.15 |
| Education | $223.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $186.66 | 2024-2025 | Lifevest |
| Asahi Intecc USA, INC. | $158.13 | 2025 | Asahi Coronary Wires |
| Abbott Laboratories | $134.02 | 2024 | Ensite |
| Novo Nordisk INC | $119.70 | 2025 | Wegovy |
| Shockwave Medical, INC | $116.84 | 2025 | |
| Novartis Pharmaceuticals Corporation | $116.19 | 2025 | |
| Amgen INC. | $109.41 | 2024 | |
| Boston Scientific Corporation | $82.69 | 2025 | Avvigo Guidance System |
| Abiomed | $18.39 | 2025 | |
| Medtronic, INC. | $16.99 | 2025 | Selectsecure |
| Kerecis Limited | $14.40 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasser Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.